Auzzi Shopping

Men's Weekly

.

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

  • Written by Auzzi Shopping
  • 87% of respondents deemed mRNA a key modality for the future
  • More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand
  • Skilled personnel, tech-transfer expertise, reliable supply chain, and regulatory guidelines critical to new technology adoption

SINGAPORE - Media OutReach - 31 May 2023 - According to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a "game-changer" for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.

Filling of Merck
Filling of Merck's synthetic cholesterol, a key component of mRNA-based vaccines and therapeutics, at the company's Darmstadt facility

"Vaccine manufacturers in APAC are looking to build capacity for mRNA technology over the next two to three years, while continuing to produce both traditional and modern cell-based vaccines," said Josephine Cheng, Senior Consultant, Process Solutions APAC at the Life Science business sector of Merck. "Across APAC, governments are investing and supportive of driving therapeutic discovery and manufacturing. With the range of tools we offer, we can better equip vaccine manufacturers to treat the regional and global population."

The study interviewed vaccine manufacturers across APAC, including research institutes, pharmaceutical and biotech companies. Eighty-seven percent deemed mRNA a promising technology, expecting it to be a key modality in the future. This is based on the perception that the mRNA platform benefits from shorter development time and templated manufacturing processes, proven efficacy, lower biohazard risk for operators, and flexibility in covering different types of diseases and variants.

Japan, South Korea, Australia, Indonesia, Singapore, China and India are among the markets actively exploring to develop mRNA technology. Over sixty percent of the vaccine makers prefer to revamp or establish new facilities especially for mRNA with expansion planned over the next two to three years.

To effectively move mRNA forward, respondents highlighted the need for skilled personnel trained in these new technologies, tech-transfer expertise, a reliable supply chain, and mRNA-specific regulatory guidelines.

Merck’s contribution to future vaccine manufacturing
Merck's Life Science business supports mRNA manufacturers helping accelerate speed to market, ensuring safety and efficacy, to reducing complexity across the entire mRNA process to help accelerate delivery of mRNA vaccines to patients worldwide. More information is available on sigmaaldrich.com/vaccines
Hashtag: #Merck

The issuer is solely responsible for the content of this announcement.

Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service.

Today's Features at Auzzi

Rethinking the Face of Home Transformation with Expert Builders in Sydney

There’s a reason some spaces feel timeless, while others, no matter how new, already look tired. It’s not always about budgets or square footage—it’s about the intelligence of transf...

Expert Solutions for Concrete Repairs Melbourne

Concrete is one of the most durable and widely used construction materials in both residential and commercial settings. However, over time, even concrete can show signs of wear and tear du...

Why Smaller Venues Are Winning Big With Community Events

Smaller venues create intimate, authentic experiences that large halls can’t replicate Local character and atmosphere turn community events into memorable gatherings Flexibility an...

Inside the Growth of Creative Work Spaces for Local Professionals

Professionals are moving away from city offices in favour of flexible, community-based work spaces These environments bring financial and social benefits to local suburbs Creative sp...

Split Corrugated Conduit and Solar Conduit: Safe and Durable Cable Management Solutions

In modern electrical and solar installations, proper cable management is non-negotiable. Split corrugated conduit and solar conduit systems play a vital role in safeguarding cables, impro...

Lighting Stores Perth: A Comprehensive Guide to Finding the Perfect Lighting Solutions

Lighting is a vital component in both residential and commercial spaces. It influences the ambiance, functionality, and even the perception of space. Lighting stores Perth serve as key de...

Outsource Loan Processing: What Mortgage Brokers Must Know

In the fast-moving world of mortgage broking, there's one reality every broker eventually faces, there’s never enough time in the day. Between juggling client meetings, chasing documents, ...